Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-08-15
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2013-08-25 (study day 11.0); relationship: POSSIBLE
mild
assessed
Mild PYREXIA — outcome: RECOVERED/RESOLVED; onset 2013-08-25 (study day 11.0); relationship: REMOTE
Data queries
No data queries.